688266.SS SHH
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
1W: -7.2%
1M: -6.5%
3M: -19.3%
YTD: +14.6%
1Y: +3.6%
3Y: +131.0%
5Y: +46.2%
¥110.00 ($16.40)
+3.34 (+3.13%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$3.0B
-1.1% ▼
5Y CAGR: +8.6%
Total Liabilities
$1.9B
+7.5% ▲
5Y CAGR: +46.5%
Shareholders Equity
$1.1B
-13.8% ▼
5Y CAGR: -7.8%
Cash & Investments
$2.0B
-7.4% ▼
5Y CAGR: +4.9%
Total Debt
$1.2B
+12.8% ▲
5Y CAGR: +89.1%
Net Debt
-$877M
+22.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.1B | $797M | $2.1B | $2.2B | $2.0B |
| Short-Term Investments | $65M | $249M | $137M | $41M | $0 |
| Cash & ST Investments | $1.2B | $1.0B | $2.2B | $2.2B | $2.0B |
| Net Receivables | $75M | $101M | $101M | $153M | $178M |
| Inventory | $52M | $99M | $111M | $183M | $173M |
| Other Current Assets | $25M | $58M | $62M | $5M | $16M |
| Total Current Assets | $1.4B | $1.3B | $2.5B | $2.6B | $2.4B |
| Property, Plant & Equip. | $189M | $247M | $271M | $363M | $490M |
| Goodwill & Intangibles | $116M | $91M | $69M | $50M | $31M |
| Long-Term Investments | -$55M | -$239M | $6M | $0 | $0 |
| Other Non-Current Assets | $12M | $38M | $20M | $15M | $6M |
| Total Non-Current Assets | $340M | $377M | $367M | $429M | $529M |
| Total Assets | $1.7B | $1.7B | $2.9B | $3.0B | $3.0B |
| — Liabilities — | |||||
| Accounts Payable | $118M | $152M | $138M | $197M | $222M |
| Short-Term Debt | $132M | $391M | $795M | $952M | $1.1B |
| Deferred Revenue | $87M | $279K | $0 | $0 | $1M |
| Other Current Liabilities | $44M | $186M | $74M | $16M | $55M |
| Total Current Liabilities | $381M | $729M | $1.1B | $1.4B | $1.4B |
| Long-Term Debt | $0 | $50M | $0 | $44M | $84M |
| Other Non-Current Liab. | $0 | $0 | $57M | $292M | $358M |
| Total Non-Current Liabilities | $112M | $152M | $107M | $379M | $456M |
| Total Liabilities | $493M | $881M | $1.2B | $1.8B | $1.9B |
| — Equity — | |||||
| Common Stock | $240M | $240M | $265M | $265M | $265M |
| Retained Earnings | -$1.2B | -$1.7B | -$2.0B | -$2.1B | -$2.3B |
| Accumulated OCI | $78M | $118M | $68M | $61M | -$14M |
| Total Stockholders Equity | $1.2B | $759M | $1.6B | $1.3B | $1.1B |
| Total Liabilities & Equity | $1.7B | $1.7B | $2.9B | $3.0B | $3.0B |
| — Key Metrics — | |||||
| Total Debt | $224M | $548M | $825M | $1.0B | $1.2B |
| Net Debt | -$913M | -$249M | -$1.2B | -$1.1B | -$877M |
| Total Investments | $10M | $10M | $143M | $41M | $0 |